Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 70

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 70
---
 uses for which the drug may be
marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4
clinical trials and surveillance to monitor the safety and efficacy of the drug candidate. The regulatory authorities may also require
risk management plans or programs as a condition of approval of Aptorum’s drug candidates (such as REMS of the FDA and risk-management
plan of the EMA), which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or
additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.
In addition, if the FDA, NMPA, EMA, Health Canada or a comparable regulatory authority approves Aptorum’s drug candidates, we will
have to comply with requirements including, for example, submissions of safety and other post-marketing information and reports, registration,
as well as continued compliance with cGCP and cGMP, for any clinical trials that we conduct post-approval.

<div align='center'>36</div>

The FDA may impose consent
decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
drug reaches the market. Later discovery of previously unknown problems with Aptorum’s drug candidates, including adverse events
of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory
requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical
studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential
consequences include, among other things:

| ● | restrictions on the marketing or manufacturing of Aptorum’s                                            
 drug candidates, withdrawal of the product from the market, or voluntary or mandatory product recalls; |

| ● | fines, untitled or warning letters, or holds on clinical trials; |

| ● | refusal by the FDA to approve pending applications or supplements                      
 to approved applications filed by us or suspension or revocation of license approvals; |

| ● | product seizure or detention, or refusal to permit the import 
 or export of Aptorum’s drug candidates; and                   |

| ● | injunctions or the imposition of civil or criminal penalties. |

The FDA strictly regulates
marketing, labeling, advertising and promotion of products that are placed on the market. Companies may promote drugs only for the approved
indications and in accordance with